Skip to main content
Resources › Psychotropics A-Z › Paliperidone | Invega | Invega
Atypical Antipsychotic

Paliperidone | Invega

Clinical Overview

Paliperidone is an atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder. It is the active metabolite of risperidone, formulated as an extended-release tablet that provides once-daily dosing with reduced risk of drug interactions compared to its parent compound.

Primary Clinical Applications

Paliperidone is indicated for schizophrenia in adults and adolescents (12-17 years) and for schizoaffective disorder as monotherapy or adjunctive treatment. It offers the efficacy of risperidone with improved pharmacokinetic properties and reduced drug interaction potential.

Mechanism and Clinical Benefits

Paliperidone antagonizes central dopamine D2 and serotonin 5-HT2A receptors, providing antipsychotic efficacy with lower risk of extrapyramidal symptoms compared to typical antipsychotics. The extended-release formulation maintains steady plasma levels throughout the day.

Dosing Advantages

The osmotic controlled-release oral delivery system (OROS) allows once-daily dosing without food restrictions. The medication is primarily renally eliminated, reducing hepatic drug interactions but requiring dose adjustment in renal impairment.

Prescribing Information

Dosing & Administration

Schizophrenia – Adults:

  • Initial: 6 mg once daily in morning
  • Range: 3-12 mg daily
  • Titration: Increase by 3 mg increments at intervals ≥5 days

Schizophrenia – Adolescents (12-17 years):

  • Weight <51 kg: 3 mg daily, maximum 6 mg daily
  • Weight ≥51 kg: 3 mg daily, maximum 12 mg daily

Schizoaffective Disorder:

  • Initial: 6 mg once daily
  • Range: 3-12 mg daily

Renal Impairment:

  • Mild (CrCl 50-80 mL/min): Maximum 6 mg daily
  • Moderate-Severe (CrCl <50 mL/min): Maximum 3 mg daily

Indications

  • Schizophrenia in adults and adolescents (12-17 years)
  • Schizoaffective disorder as monotherapy or adjunct to mood stabilizers/antidepressants

Contraindications

  • Known hypersensitivity to paliperidone, risperidone, or any component

Warnings & Precautions

  • Boxed Warning: Increased mortality in elderly patients with dementia-related psychosis
  • Cerebrovascular events: Increased risk in dementia patients
  • Neuroleptic malignant syndrome: Discontinue if suspected
  • QT prolongation: Use caution with cardiac risk factors
  • Tardive dyskinesia: Risk increases with treatment duration
  • Hyperglycemia: Monitor glucose in diabetes patients

Drug Interactions

  • CNS depressants: Enhanced sedation
  • QT-prolonging drugs: Additive QT effects
  • Dopamine agonists: Antagonistic effects
  • Carbamazepine: Increased paliperidone clearance

Adverse Reactions

Common (≥5%):

  • Extrapyramidal symptoms, somnolence, dizziness, dyspepsia

Metabolic:

  • Weight gain, hyperglycemia, hyperprolactinemia

Special Populations

  • Renal Impairment: Dose reduction required
  • Pregnancy: Use only if benefits outweigh risks
  • Elderly: Increased mortality risk in dementia patients
  • Adolescents: Weight-based dosing required
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.